NASDAQ:ADXS - Advaxis Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.80 -0.03 (-1.64 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$1.80
Today's Range$1.79 - $1.84
52-Week Range$1.51 - $8.82
Volume206,794 shs
Average Volume537,751 shs
Market Capitalization$95.73 million
P/E Ratio-0.78
Dividend YieldN/A
Beta1.25

About Advaxis (NASDAQ:ADXS)

Advaxis logoAdvaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based immunotherapies in the United States. It is developing Axalimogene filolisbac and ADXS-Dual that are Lm-LLO immunotherapy product candidates for the treatment of human papilloma virus associated cancers, including cervical, and head and neck cancers. The company is also developing Axalimogene filolisbac for the treatment of anal cancer; ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is designed to target the prostate specific antigen associated with prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product candidate that is designed to create individualized therapies by activating the patient's immune system to respond against multiple mutations or neoantigens. In addition, it is developing ADXS-HOT for generating potent anti-cancer immunity; and ADXS-HER2, an Lm technology antigen delivery product candidate that is designed to target HER2 expressing solid tumors, including human and canine osteosarcoma. The company has collaboration and licensing agreements with Bristol-Myers Squibb Company; Amgen Inc.; Sellas Life Science Group; Merck & Co., Inc.; MedImmune/AstraZeneca PLC; Especificos Stendhal SA de CV; Aratana Therapeutics Inc.; and Global BioPharma Inc. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.

Receive ADXS News and Ratings via Email

Sign-up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ADXS
CUSIPN/A
Phone609-452-9813

Debt

Debt-to-Equity RatioN/A
Current Ratio2.96
Quick Ratio2.96

Price-To-Earnings

Trailing P/E Ratio-0.78
Forward P/E Ratio-1.04
P/E GrowthN/A

Sales & Book Value

Annual Sales$12.03 million
Price / Sales7.83
Cash FlowN/A
Price / CashN/A
Book Value$1.32 per share
Price / Book1.36

Profitability

EPS (Most Recent Fiscal Year)($2.31)
Net Income$-93,430,000.00
Net Margins-940.64%
Return on Equity-149.14%
Return on Assets-92.30%

Miscellaneous

Employees108
Outstanding Shares52,310,000

Advaxis (NASDAQ:ADXS) Frequently Asked Questions

What is Advaxis' stock symbol?

Advaxis trades on the NASDAQ under the ticker symbol "ADXS."

How were Advaxis' earnings last quarter?

Advaxis (NASDAQ:ADXS) released its earnings results on Monday, March, 12th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.55) by $0.06. The biotechnology company earned $2.06 million during the quarter, compared to analyst estimates of $3.03 million. Advaxis had a negative return on equity of 149.14% and a negative net margin of 940.64%. View Advaxis' Earnings History.

When is Advaxis' next earnings date?

Advaxis is scheduled to release their next quarterly earnings announcement on Monday, June, 4th 2018. View Earnings Estimates for Advaxis.

What price target have analysts set for ADXS?

2 brokerages have issued 1 year price targets for Advaxis' shares. Their forecasts range from $5.00 to $6.00. On average, they expect Advaxis' stock price to reach $5.50 in the next twelve months. View Analyst Ratings for Advaxis.

What are Wall Street analysts saying about Advaxis stock?

Here are some recent quotes from research analysts about Advaxis stock:
  • 1. HC Wainwright analysts commented, "Olga Smolentseva, Ph.D. – (646-975-6966) / [email protected] ADXS-NEO Can Incite Immune Responses With Non-Immunogenic" Antigens; Reiterate Buy ADXS-NEO demonstrates potential in two preclinical studies. On April 16, Advaxis presented results from two preclinical studies of ADXS-NEO at the 2018 American Association for Cancer Research (AACR) Annual Meeting. Recall, ADXS-NEO is a personalized therapy targeting tumor neoantigens developed from Advaxis’ Lm-LLO listeria delivery platform. ADXS-NEO was licensed to Amgen (AMGN; not rated) in 2016 for $40M upfront and up to $475M in development, regulatory and sales milestone payments and up to mid-double-digit royalties on worldwide sales. In the first of the two studies, the company demonstrated that ADXS-NEO is able to target frameshift mutations and drive a neoantigen-specific antitumor immune response in MC38 and CT26 mouse tumor models." (4/17/2018)
  • 2. Cantor Fitzgerald analysts commented, "Multiple inflection points expected in 2018, including an update on the AIM2CERV Phase III study and potential preliminary data from Part B of the Phase I/II study of ADXS-PSA in combination with Keytruda." (9/25/2017)

Who are some of Advaxis' key competitors?

Who are Advaxis' key executives?

Advaxis' management team includes the folowing people:
  • Ms. Sara M. Bonstein, Exec. VP, Principal Accounting Officer, CFO & Corp. Sec. (Age 37)
  • Dr. Robert G. Petit, Exec. VP & Chief Scientific Officer (Age 58)
  • Mr. Anthony A. Lombardo, Interim Chief Exec. Officer (Age 69)
  • Mr. Christopher Duke, Sr. VP & COO
  • Mr. Mayo Pujols, Sr. VP of Technical Operations

Has Advaxis been receiving favorable news coverage?

Headlines about ADXS stock have been trending somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Advaxis earned a news impact score of 0.11 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 47.50 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are Advaxis' major shareholders?

Advaxis' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.59%) and DAFNA Capital Management LLC (1.33%). Company insiders that own Advaxis stock include Adage Capital Partners Gp, LL, Anthony A Lombardo, Daniel O'connor, David Sidransky, Gregory T Mayes, Richard J Berman, Robert Petit, Sara Bonstein and Thomas J Mckearn. View Institutional Ownership Trends for Advaxis.

Which institutional investors are buying Advaxis stock?

ADXS stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc. and DAFNA Capital Management LLC. View Insider Buying and Selling for Advaxis.

How do I buy shares of Advaxis?

Shares of ADXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Advaxis' stock price today?

One share of ADXS stock can currently be purchased for approximately $1.80.

How big of a company is Advaxis?

Advaxis has a market capitalization of $95.73 million and generates $12.03 million in revenue each year. The biotechnology company earns $-93,430,000.00 in net income (profit) each year or ($2.31) on an earnings per share basis. Advaxis employs 108 workers across the globe.

How can I contact Advaxis?

Advaxis' mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The biotechnology company can be reached via phone at 609-452-9813 or via email at [email protected]


MarketBeat Community Rating for Advaxis (ADXS)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  231 (Vote Outperform)
Underperform Votes:  124 (Vote Underperform)
Total Votes:  355
MarketBeat's community ratings are surveys of what our community members think about Advaxis and other stocks. Vote "Outperform" if you believe ADXS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADXS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Advaxis (NASDAQ:ADXS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Advaxis in the last 12 months. Their average twelve-month price target is $5.50, suggesting that the stock has a possible upside of 205.56%. The high price target for ADXS is $6.00 and the low price target for ADXS is $5.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.50$5.50$21.00$21.00
Price Target Upside: 205.56% upside212.50% upside636.84% upside572.00% upside

Advaxis (NASDAQ:ADXS) Consensus Price Target History

Price Target History for Advaxis (NASDAQ:ADXS)

Advaxis (NASDAQ:ADXS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/17/2018HC WainwrightReiterated RatingBuy$6.00HighView Rating Details
3/13/2018Cantor FitzgeraldLower Price TargetHold ➝ Overweight$19.00 ➝ $5.00HighView Rating Details
9/9/2016Jefferies GroupReiterated RatingBuy$24.00N/AView Rating Details
8/3/2016BarclaysBoost Price TargetOverweight$15.00 ➝ $20.00N/AView Rating Details
7/7/2016FBR & CoReiterated RatingOutperform$34.00N/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Advaxis (NASDAQ:ADXS) Earnings History and Estimates Chart

Earnings by Quarter for Advaxis (NASDAQ:ADXS)

Advaxis (NASDAQ:ADXS) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20181($0.42)($0.42)($0.42)
Q3 20181($0.45)($0.45)($0.45)
Q4 20181($0.43)($0.43)($0.43)

Advaxis (NASDAQ ADXS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
6/4/2018($0.52)N/AView Earnings Details
3/12/2018Q1 2018($0.55)($0.49)$3.03 million$2.06 millionViewListenView Earnings Details
12/20/2017Q4 2017($0.55)($0.57)$3.05 million$1.76 millionViewListenView Earnings Details
9/11/2017Q3($0.53)($0.80)$3.43 million$3.05 millionViewN/AView Earnings Details
6/6/2017Q2 2017($0.49)($0.51)$3.79 million$3.43 millionViewN/AView Earnings Details
3/10/2017Q1 2017($0.5150)($0.43)$2.15 million$3.79 millionViewN/AView Earnings Details
1/9/2017Q4 2016($0.55)$3.75 millionViewN/AView Earnings Details
9/8/2016Q3 2016($0.22)($0.48)ViewN/AView Earnings Details
6/8/2016Q2 2016($0.54)($0.45)$0.13 millionViewN/AView Earnings Details
2/26/2016Q1 2016($0.41)($0.59)$0.10 million$0.25 millionViewN/AView Earnings Details
1/8/2016Q4 2015($0.37)ViewN/AView Earnings Details
9/11/2015Q3 2015($0.31)($0.44)ViewN/AView Earnings Details
6/15/2015Q2 2015($0.27)($0.52)ViewN/AView Earnings Details
3/13/2015Q1 2015($0.31)($0.33)ViewN/AView Earnings Details
9/9/2014Q3 2014($0.25)($0.30)ViewN/AView Earnings Details
6/9/2014Q3 2014($0.25)($0.30)$1.00 millionViewN/AView Earnings Details
3/17/2014Q1 2014($0.25)($0.37)ViewN/AView Earnings Details
1/29/2014Q4 2013($0.25)($0.97)ViewN/AView Earnings Details
9/16/2013Q3 2013($0.86)($0.37)ViewN/AView Earnings Details
6/14/2013Q2 2013($1.25)($156.25)ViewN/AView Earnings Details
3/25/2013Q1 2013($107.50)($206.25)ViewN/AView Earnings Details
2/13/2013Q4 2010($67.50)ViewN/AView Earnings Details
9/12/2011Q3 2011($1.00)ViewN/AView Earnings Details
6/14/2011Q2 2011($2.38)ViewN/AView Earnings Details
3/17/2011Q1 2011($2.50)ViewN/AView Earnings Details
6/3/2010Q2 2010($3.13)ViewN/AView Earnings Details
2/19/2010Q4 2009$1.50ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Advaxis (NASDAQ:ADXS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Advaxis (NASDAQ ADXS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.21%
Institutional Ownership Percentage: 33.90%
Insider Trading History for Advaxis (NASDAQ:ADXS)
Institutional Ownership by Quarter for Advaxis (NASDAQ:ADXS)

Advaxis (NASDAQ ADXS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/2/2018Robert PetitInsiderSell2,193$1.62$3,552.66View SEC Filing  
2/2/2018Anthony A LombardoCEOSell32$2.93$93.7692,903View SEC Filing  
1/3/2018Sara BonsteinCFOSell5,224$3.18$16,612.32229,237View SEC Filing  
11/6/2017Robert PetitInsiderSell3,723$3.30$12,285.90220,917View SEC Filing  
11/6/2017Sara BonsteinCFOSell3,862$3.30$12,744.60227,908View SEC Filing  
11/2/2017Anthony A LombardoCEOSell24$3.19$76.5692,935View SEC Filing  
11/2/2017Robert PetitInsiderSell12,625$3.19$40,273.75237,265View SEC Filing  
11/2/2017Sara BonsteinCFOSell12,734$3.19$40,621.46244,504View SEC Filing  
10/11/2017Adage Capital Partners Gp, L.LMajor ShareholderSell600,000$4.30$2,580,000.00View SEC Filing  
9/26/2017Adage Capital Partners Gp, L.LMajor ShareholderSell1,239,323$4.42$5,477,807.66View SEC Filing  
3/31/2017Robert PetitInsiderSell2,454$8.24$20,220.96122,051View SEC Filing  
12/30/2016Sara BonsteinCFOSell5,520$7.37$40,682.40131,963View SEC Filing  
12/20/2016Thomas J MckearnDirectorSell12,316$8.08$99,513.2869,804View SEC Filing  
11/2/2016Daniel O'connorCEOSell8,240$8.32$68,556.80303,127View SEC Filing  
11/2/2016Robert PetitInsiderSell2,797$8.32$23,271.04123,659View SEC Filing  
10/25/2016Gregory T MayesInsiderSell19,162$8.23$157,703.26103,087View SEC Filing  
8/9/2016David SidranskyDirectorSell22,808$15.01$342,348.0891,759View SEC Filing  
8/8/2016Richard J BermanDirectorSell18,000$15.21$273,780.0066,430View SEC Filing  
5/13/2016Thomas J MckearnDirectorSell4,100$7.45$30,545.0082,120View SEC Filing  
5/2/2016Daniel O'connorCEOSell8,237$7.51$61,859.87316,661View SEC Filing  
5/2/2016Robert PetitInsiderSell2,785$7.51$20,915.35128,025View SEC Filing  
3/31/2016Robert PetitInsiderSell3,325$9.13$30,357.25131,164View SEC Filing  
3/16/2016Thomas J MckearnDirectorSell14,000$8.25$115,500.0086,220View SEC Filing  
2/24/2016Sara BonsteinCFOSell15,037$5.58$83,906.4679,980View SEC Filing  
1/29/2016Daniel O'connorCEOSell8,818$6.88$60,667.84313,394View SEC Filing  
1/29/2016Robert PetitinsiderSell3,099$6.88$21,321.12130,557View SEC Filing  
10/26/2015Gregory T MayesCOOSell19,231$11.63$223,656.53119,821View SEC Filing  
10/20/2015David J MauroInsiderSell24,586$10.08$247,826.88165,932View SEC Filing  
8/24/2015Adage Capital Partners Gp LlcMajor ShareholderBuy300,000$14.15$4,245,000.00View SEC Filing  
4/30/2015Adage Capital Partners Gp LlcMajor ShareholderBuy500,000$19.00$9,500,000.00View SEC Filing  
2/18/2015Adage Capital Partners Gp LlcMajor ShareholderBuy684,762$7.50$5,135,715.00View SEC Filing  
5/9/2014Richard J BermanDirectorSell14,530$2.63$38,213.90View SEC Filing  
3/31/2014Daniel O'connorCEOBuy3,333$3.00$9,999.00View SEC Filing  
10/24/2013Daniel O'connorCEOBuy13,500$4.00$54,000.00View SEC Filing  
10/24/2013Mark J RosenblumCFOBuy12,000$4.00$48,000.00View SEC Filing  
10/24/2013Robert PetitInsiderBuy12,800$4.00$51,200.00View SEC Filing  
10/24/2013Roni AppelDirectorBuy12,500$4.00$50,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Advaxis (NASDAQ ADXS) News Headlines

Source:
DateHeadline
 Analysts Expect Advaxis (ADXS) Will Announce Quarterly Sales of $2.43 Million Analysts Expect Advaxis (ADXS) Will Announce Quarterly Sales of $2.43 Million
www.americanbankingnews.com - May 24 at 2:30 AM
Zacks: Brokerages Expect Advaxis (ADXS) to Announce -$0.41 Earnings Per ShareZacks: Brokerages Expect Advaxis (ADXS) to Announce -$0.41 Earnings Per Share
www.americanbankingnews.com - May 22 at 7:20 PM
Analysis: Positioning to Benefit within Advaxis, elf Beauty, Heron Therapeutics, PVH, Energy Recovery, and AO Smith ...Analysis: Positioning to Benefit within Advaxis, elf Beauty, Heron Therapeutics, PVH, Energy Recovery, and AO Smith ...
www.nasdaq.com - May 14 at 10:41 AM
Advaxis (ADXS) Says Presented Preclinical Data Show Potential for ADXS-NEO as Anti-Cancer ImmunotherapyAdvaxis (ADXS) Says Presented Preclinical Data Show Potential for ADXS-NEO as Anti-Cancer Immunotherapy
www.streetinsider.com - May 11 at 10:15 AM
Recently Presented Preclinical Data Show Potential for ADXS-NEO as Anti-Cancer Immunotherapy AgentRecently Presented Preclinical Data Show Potential for ADXS-NEO as Anti-Cancer Immunotherapy Agent
finance.yahoo.com - May 11 at 10:15 AM
Advaxis (ADXS) Expected to Post Quarterly Sales of $2.43 MillionAdvaxis (ADXS) Expected to Post Quarterly Sales of $2.43 Million
www.americanbankingnews.com - May 7 at 4:26 AM
Advaxis (ADXS) Expected to Announce Earnings of -$0.41 Per ShareAdvaxis (ADXS) Expected to Announce Earnings of -$0.41 Per Share
www.americanbankingnews.com - May 5 at 9:32 AM
Advaxis (ADXS) Stock Rating Upgraded by ValuEngineAdvaxis (ADXS) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - May 4 at 3:35 PM
Form 8-K Advaxis, Inc. For: Apr 23Form 8-K Advaxis, Inc. For: Apr 23
www.streetinsider.com - April 24 at 9:10 AM
BRIEF-Advaxis Announces Executive Leadership ChangesBRIEF-Advaxis Announces Executive Leadership Changes
www.reuters.com - April 23 at 9:36 AM
Advaxis Announces Executive Leadership ChangesAdvaxis Announces Executive Leadership Changes
finance.yahoo.com - April 23 at 9:36 AM
$2.43 Million in Sales Expected for Advaxis (ADXS) This Quarter$2.43 Million in Sales Expected for Advaxis (ADXS) This Quarter
www.americanbankingnews.com - April 20 at 4:28 AM
Advaxis (ADXS) Says Preclinical Data Highlighting ADXS-Hot as Immunotherapy Presented in Poster Discussion at ...Advaxis (ADXS) Says Preclinical Data Highlighting ADXS-Hot as Immunotherapy Presented in Poster Discussion at ...
www.streetinsider.com - April 18 at 9:36 AM
Advaxis (ADXS) Expected to Post Earnings of -$0.41 Per ShareAdvaxis (ADXS) Expected to Post Earnings of -$0.41 Per Share
www.americanbankingnews.com - April 18 at 9:35 AM
Preclinical Data Highlighting ADXS-Hot as Immunotherapy with Potential to Target Hotspot Cancer Mutations across Multiple Cancer Types Presented in Poster Discussion at The AACR Annual MeetingPreclinical Data Highlighting ADXS-Hot as Immunotherapy with Potential to Target Hotspot Cancer Mutations across Multiple Cancer Types Presented in Poster Discussion at The AACR Annual Meeting
finance.yahoo.com - April 17 at 9:22 AM
Advaxis (ADXS) "Buy" Rating Reaffirmed at HC WainwrightAdvaxis' (ADXS) "Buy" Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - April 17 at 7:39 AM
Advaxis (ADXS) Rating Lowered to Sell at BidaskClubAdvaxis (ADXS) Rating Lowered to Sell at BidaskClub
www.americanbankingnews.com - April 15 at 12:36 AM
Advaxis (ADXS) Downgraded by ValuEngineAdvaxis (ADXS) Downgraded by ValuEngine
www.americanbankingnews.com - April 8 at 9:37 AM
What Is The Future Prospect For Healthcare And Advaxis Inc (NASDAQ:ADXS)?What Is The Future Prospect For Healthcare And Advaxis Inc (NASDAQ:ADXS)?
finance.yahoo.com - April 4 at 4:51 PM
 Analysts Expect Advaxis, Inc. (ADXS) Will Announce Quarterly Sales of $2.43 Million Analysts Expect Advaxis, Inc. (ADXS) Will Announce Quarterly Sales of $2.43 Million
www.americanbankingnews.com - April 3 at 4:11 AM
Data Highlighting Advaxis ADXS-PSA Accepted as Poster Presentation at the American Society of Clinical Oncology ...Data Highlighting Advaxis' ADXS-PSA Accepted as Poster Presentation at the American Society of Clinical Oncology ...
www.businesswire.com - April 2 at 10:01 AM
Data Highlighting Advaxis’ ADXS-PSA Accepted as Poster Presentation at the American Society of Clinical Oncology Annual MeetingData Highlighting Advaxis’ ADXS-PSA Accepted as Poster Presentation at the American Society of Clinical Oncology Annual Meeting
finance.yahoo.com - April 2 at 10:01 AM
-$0.41 Earnings Per Share Expected for Advaxis, Inc. (ADXS) This Quarter-$0.41 Earnings Per Share Expected for Advaxis, Inc. (ADXS) This Quarter
www.americanbankingnews.com - April 1 at 7:23 AM
Advaxis Inc (NASDAQ:ADXS): Does The -36.80% Earnings Drop Reflect A Longer Term Trend?Advaxis Inc (NASDAQ:ADXS): Does The -36.80% Earnings Drop Reflect A Longer Term Trend?
finance.yahoo.com - March 27 at 9:12 AM
Advaxis Announces Four Poster Presentations Highlighting Lm-based Antigen Delivery Technology at AACR 2018Advaxis Announces Four Poster Presentations Highlighting Lm-based Antigen Delivery Technology at AACR 2018
finance.yahoo.com - March 26 at 10:09 AM
Advaxis (ADXS) Upgraded to Sell at ValuEngineAdvaxis (ADXS) Upgraded to Sell at ValuEngine
www.americanbankingnews.com - March 25 at 9:16 PM
Advaxis (ADXS) PT Lowered to $5.00Advaxis (ADXS) PT Lowered to $5.00
www.americanbankingnews.com - March 18 at 12:26 PM
Edited Transcript of ADXS earnings conference call or presentation 12-Mar-18 8:30pm GMTEdited Transcript of ADXS earnings conference call or presentation 12-Mar-18 8:30pm GMT
finance.yahoo.com - March 18 at 9:40 AM
Zacks: Brokerages Anticipate Advaxis, Inc. (ADXS) Will Announce Quarterly Sales of $2.43 MillionZacks: Brokerages Anticipate Advaxis, Inc. (ADXS) Will Announce Quarterly Sales of $2.43 Million
www.americanbankingnews.com - March 17 at 8:38 AM
FY2018 EPS Estimates for Advaxis, Inc. Lifted by Cantor Fitzgerald (ADXS)FY2018 EPS Estimates for Advaxis, Inc. Lifted by Cantor Fitzgerald (ADXS)
www.americanbankingnews.com - March 16 at 10:48 AM
Q2 2018 Earnings Estimate for Advaxis, Inc. (ADXS) Issued By Jefferies GroupQ2 2018 Earnings Estimate for Advaxis, Inc. (ADXS) Issued By Jefferies Group
www.americanbankingnews.com - March 15 at 7:54 AM
Zacks: Brokerages Anticipate Advaxis, Inc. (ADXS) Will Post Earnings of -$0.59 Per ShareZacks: Brokerages Anticipate Advaxis, Inc. (ADXS) Will Post Earnings of -$0.59 Per Share
www.americanbankingnews.com - March 15 at 5:18 AM
Advaxis (ADXS) Given a $6.00 Price Target by HC Wainwright AnalystsAdvaxis (ADXS) Given a $6.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - March 14 at 10:50 PM
Advaxis shares drop as cancer-drug study on hold after death - MarketWatchAdvaxis shares drop as cancer-drug study on hold after death - MarketWatch
www.marketwatch.com - March 14 at 12:18 PM
Advaxis Reports Fiscal 2018 First Quarter Financial Results and Announces Clinical Hold in Axalimogene Filolisbac ... - Business Wire (press release)Advaxis Reports Fiscal 2018 First Quarter Financial Results and Announces Clinical Hold in Axalimogene Filolisbac ... - Business Wire (press release)
www.businesswire.com - March 14 at 12:18 PM
Mid-Day Market Update: Crude Oil Down 1.5%; Proteostasis Therapeutics Shares Spike HigherMid-Day Market Update: Crude Oil Down 1.5%; Proteostasis Therapeutics Shares Spike Higher
www.benzinga.com - March 13 at 4:58 PM
Advaxis (ADXS) CEO Tony Lombardo on Q1 2018 Results - Earnings Call TranscriptAdvaxis' (ADXS) CEO Tony Lombardo on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - March 13 at 10:54 AM
Advaxis to Present at Upcoming March ConferencesAdvaxis to Present at Upcoming March Conferences
finance.yahoo.com - March 13 at 10:54 AM
Advaxis shares drop as cancer-drug study on hold after deathAdvaxis shares drop as cancer-drug study on hold after death
finance.yahoo.com - March 13 at 10:54 AM
Advaxis (ADXS) Issues Quarterly  Earnings ResultsAdvaxis (ADXS) Issues Quarterly Earnings Results
www.americanbankingnews.com - March 13 at 10:20 AM
Technical Perspectives on Biotech Stocks -- 22nd Century, Abeona Therapeutics, Advaxis, and Adverum BiotechnologiesTechnical Perspectives on Biotech Stocks -- 22nd Century, Abeona Therapeutics, Advaxis, and Adverum Biotechnologies
www.bizjournals.com - March 12 at 4:43 PM
Advaxis Reports Fiscal 2018 First Quarter Financial Results and Announces Clinical Hold in Axalimogene Filolisbac Phase 1/2 Combination Study with AstraZeneca’s IMFINZI® (Durvalumab)Advaxis Reports Fiscal 2018 First Quarter Financial Results and Announces Clinical Hold in Axalimogene Filolisbac Phase 1/2 Combination Study with AstraZeneca’s IMFINZI® (Durvalumab)
finance.yahoo.com - March 12 at 4:43 PM
Should You Have Advaxis Inc’s (NASDAQ:ADXS) In Your Portfolio?Should You Have Advaxis Inc’s (NASDAQ:ADXS) In Your Portfolio?
finance.yahoo.com - March 12 at 4:43 PM
Advaxis reports 1Q lossAdvaxis reports 1Q loss
finance.yahoo.com - March 12 at 4:43 PM
Advaxis, Inc. (ADXS) Short Interest UpdateAdvaxis, Inc. (ADXS) Short Interest Update
www.americanbankingnews.com - March 12 at 1:24 AM
How Do Analysts See Advaxis Inc (NASDAQ:ADXS) Performing Over The Next Few Years?How Do Analysts See Advaxis Inc (NASDAQ:ADXS) Performing Over The Next Few Years?
finance.yahoo.com - March 9 at 4:54 PM
Advaxis to Host Business Update and First Quarter 2018 Financial Results Conference Call on March 12, 2018Advaxis to Host Business Update and First Quarter 2018 Financial Results Conference Call on March 12, 2018
finance.yahoo.com - March 9 at 10:59 AM
Advaxis Inc (NASDAQ:ADXS): Is Breakeven Near?Advaxis Inc (NASDAQ:ADXS): Is Breakeven Near?
finance.yahoo.com - March 8 at 10:32 AM
Advaxis (ADXS) Set to Announce Earnings on ThursdayAdvaxis (ADXS) Set to Announce Earnings on Thursday
www.americanbankingnews.com - March 1 at 1:30 AM
 Brokerages Expect Advaxis, Inc. (ADXS) Will Announce Quarterly Sales of $3.03 Million Brokerages Expect Advaxis, Inc. (ADXS) Will Announce Quarterly Sales of $3.03 Million
www.americanbankingnews.com - February 28 at 1:48 PM

SEC Filings

Advaxis (NASDAQ:ADXS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Advaxis (NASDAQ:ADXS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Advaxis (NASDAQ ADXS) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.